Ashfa Anwar: While The World Is Editing Genes, Sri Lanka Is Still Thawing Plasma for Hemophilia
Ashfa Anwar, Biomedical Researcher from International College of Business and Technology, shared on LinkedIn:
”While the world is editing genes, Sri Lanka is still thawing plasma.
Let that sink in for a second.
I recently did a deep dive into Hemophilia A management for a literature review and what I found was honestly shocking.
Not because of how far science has come.
But because of how unevenly that progress is distributed.
Here’s what the world looks like right now:
- From plasma-based treatments like FFP and cryprecipitate to factor replacement, recombinant therapies, and emicizumab, the newest management startergy. Care has become progressively safer, more targeted, and more effective
- Gene Therapy – now at the frontier. Using vectors to deliver a functional gene directly into hepatocytes, enabling endogenous Factor VIII production.
And Sri Lanka?
Largely still at plasma based treatments and factor replacement
Recombinant therapy and emicizumab remain limited, with emicizumab mainly reserved for severe cases or patients with inhibitors
Gene therapy is not even part of the conversation here.
This is not criticism. It is a reality check.
Because the gap here is not scientific. It is systemic.
We are not waiting for breakthroughs. They already exist.
We are waiting for access, policy, and prioritisation to catch up.
So the real question is not ‘what is the future of haemophilia care?’
It is this:
Who gets to live in that future, and who gets left behind?”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research